Base de dados : MEDLINE
Pesquisa : F04.096.712 [Categoria DeCS]
Referências encontradas : 3236 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 324 ir para página                         

  1 / 3236 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29173781
[Au] Autor:Stepanova E; Findling RL
[Ad] Endereço:Johns Hopkins University School of Medicine, Childrens' Mental Health Center, 401 North Caroline Street, Baltimore, MD 21231, USA. Electronic address: estepan2@jhmi.edu.
[Ti] Título:Psychopharmacology of Bipolar Disorders in Children and Adolescents.
[So] Source:Pediatr Clin North Am;64(6):1209-1222, 2017 Dec.
[Is] ISSN:1557-8240
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Bipolar disorder is a debilitating illness that often leads to functional impairment when untreated. Monotherapy with mood stabilizers is preferable, although combination therapy may be necessary in refractory cases. Most studies focus on the use of lithium, anticonvulsants, and second-generation antipsychotics in the treatment of acute manic or depressive phases, as well as maintaining adequate response after the episode. More research is needed in the area of psychopharmacology of pediatric bipolar disorder to bridge the gap between clinical needs and the available data.
[Mh] Termos MeSH primário: Antipsicóticos/uso terapêutico
Transtorno Bipolar/tratamento farmacológico
Psicofarmacologia/métodos
[Mh] Termos MeSH secundário: Adolescente
Criança
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antipsychotic Agents)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171204
[Lr] Data última revisão:
171204
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE


  2 / 3236 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28595685
[Au] Autor:Sasson E; James M; Wubshet B; Todorov D; Cohen H
[Ti] Título:Implementing Psychopharmacology Rounds in a Nursing Facility to Improve Antipsychotic Usage.
[So] Source:Consult Pharm;32(6):352-359, 2017 Jun 01.
[Is] ISSN:0888-5109
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Evaluate whether implementing of pharmacy-led psychopharmacology rounds in a nursing facility will improve the rate of antipsychotic use. DESIGN: Single-center, prospective; medication use evaluation (MUE). SETTING: Rutland Nursing Home, Brooklyn, New York. PARTICIPANTS: Nursing facility residents, excluding the pediatric unit. INTERVENTIONS: Weekly interdisciplinary psychopharmacology rounds that include: clinical pharmacists, nurse managers, medical director, social workers, and administration. Antipsychotics were analyzed for all residents for appropriateness of use, proper documentation, and adequate monitoring. MAIN OUTCOME MEASURE: Assess the overall rate of reduction of antipsychotic use after implementation of psychopharmacology rounds. Secondary outcomes assessed improvements in monitoring and documentation for residents on antipsychotics. RESULTS: A total of 81 residents were evaluated over the six-month MUE. Of those residents, 20 had their antipsychotics discontinued, and 11 had their antipsychotics tapered. The overall use of antipsychotics decreased from 14.6% (62/422) to 12.2% (50/411) (P = 0.285). Compliance with indications generally approved by the Centers for Medicare & Medicaid Services improved from 65% (37/57) to 85% (46/54) (P = 0.008). Matching indications on the psychiatry consult and the medication order improved from 58% (33/57) to 80% (43/54) (P = 0.015). Metabolic laboratory monitoring improved from 58% (33/57) to 83% (45/54) (P = 0.003). Improvements in timeliness of psychiatry and ophthalmology consults were not statistically significant. CONCLUSION: Implementing interdisciplinary psycho-pharmacology rounds in a nursing facility resulted in a reduction of inappropriate antipsychotic use and improved monitoring and documentation.
[Mh] Termos MeSH primário: Antipsicóticos/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Documentação/métodos
Feminino
Seres Humanos
Masculino
Meia-Idade
New York
Casas de Saúde
Assistência Farmacêutica
Farmacêuticos
Estudos Prospectivos
Psicofarmacologia/métodos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antipsychotic Agents)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171103
[Lr] Data última revisão:
171103
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170610
[St] Status:MEDLINE
[do] DOI:10.4140/TCP.n.2017.352


  3 / 3236 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28287671
[Au] Autor:Leahy LG
[Ti] Título:Genetic Testing for Psychopharmacology: Is It Ready for Prime Time?
[So] Source:J Psychosoc Nurs Ment Health Serv;55(3):19-23, 2017 Mar 01.
[Is] ISSN:0279-3695
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Genetic testing in psychiatric practice may be a beneficial adjunct to the nursing toolbox of considerations used to improve patient outcomes. Since 2004, the psychiatric community has used genotyping to personalize medication options for their patients. Although not a definitive or exact science, pharmacogenetic testing for psychopharmacological treatment options offers nurses and their patients insights into potential treatments that will reduce the current trial-and-error prescribing practices and more quickly improve patients' quality of life. The current article guides nurses through the process of conducting genetic testing, interpreting the results, and applying the results in clinical practice using a fictitious case example. [Journal of Psychosocial Nursing and Mental Health Services, 55(3), 19-23.].
[Mh] Termos MeSH primário: Interações Medicamentosas
Testes Genéticos/métodos
Enfermagem Psiquiátrica
Psicofarmacologia
[Mh] Termos MeSH secundário: Adulto
Prática Avançada de Enfermagem
Prescrições de Medicamentos
Feminino
Genótipo
Seres Humanos
Transtornos Mentais/tratamento farmacológico
Papel do Profissional de Enfermagem
Enfermagem Psiquiátrica/normas
Qualidade de Vida
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170717
[Lr] Data última revisão:
170717
[Sb] Subgrupo de revista:IM; N
[Da] Data de entrada para processamento:170314
[St] Status:MEDLINE
[do] DOI:10.3928/02793695-20170301-02


  4 / 3236 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28166081
[Au] Autor:de Leon J; De Las Cuevas C
[Ad] Endereço:From the *University of Kentucky Mental Health Research Center at Eastern State Hospital, Lexington, Kentucky; and †Psychiatry and Neurosciences Research Group (CTS-549), Institute of Neurosciences, University of Granada, Granada; ‡Biomedical Research Centre in Mental Health Net (CIBERSAM), Santiago Apostol Hospital, University of the Basque Country, Vitoria; and §Department of Internal Medicine, Dermatology and Psychiatry, University of La Laguna, Canary Islands, Spain.
[Ti] Título:The Art of Pharmacotherapy: Reflections on Pharmacophobia.
[So] Source:J Clin Psychopharmacol;37(2):131-137, 2017 Apr.
[Is] ISSN:1533-712X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE/BACKGROUND: This commentary deals with the neglected issue of the art of psychopharmacology by recounting the authors' journeys. METHODS/PROCEDURES: First, a model of medical science situated within the history of medicine is described including (1) a limitation of the mathematical model of science, (2) the distinction between mechanistic science and mathematical science, (3) how this distinction is applied to medicine, and (4) how this distinction is applied to explain pharmacology to psychiatrists. Second, the neglected art of psychopharmacology is addressed by explaining (1) where the art of psychopharmacotherapy was hiding in the first author's psychopharmacology research, (2) how the Health Belief Model was applied to the art of medicine, (3) how the second author became interested in the Health Belief Model, and (4) his studies introducing the Health Belief Model in psychopharmacology. The authors' collaboration led to: (1) study of the effect of pharmacophobia on poor adherence and (2) reflection on the limits of the art of psychopharmacology. FINDINGS/RESULTS: Low adherence was found in 45% (116/258) of psychiatric patients with pharmacophobia versus 22% (149/682) in those with no pharmacophobia, providing an odds ratio of 2.9 (95% confidence interval, 2.2-4.0) and an adjusted odds ratio of 2.5 (95% confidence interval, 1.8-3.5) after adjusting for other variables contributing to poor adherence. IMPLICATIONS/CONCLUSIONS: Different cognitive patterns in different patients may contribute to poor adherence. Specific interventions targeting these varying cognitive styles may be needed in different patients to improve drug adherence.
[Mh] Termos MeSH primário: Adesão à Medicação
Transtornos Mentais/tratamento farmacológico
Transtornos Fóbicos
Psicofarmacologia/normas
[Mh] Termos MeSH secundário: Seres Humanos
Modelos Teóricos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170626
[Lr] Data última revisão:
170626
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170207
[St] Status:MEDLINE
[do] DOI:10.1097/JCP.0000000000000675


  5 / 3236 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28130017
[Au] Autor:Gutsche M; Burri A
[Ad] Endereço:Department of Psychology, University of Zurich, Zurich, Switzerland.
[Ti] Título:What Women Want-An Explorative Study on Women's Attitudes Toward Sexuality Boosting Medication in a Sample of Swiss Women.
[So] Source:J Sex Med;14(3):404-412, 2017 Mar.
[Is] ISSN:1743-6109
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The recent approval of flibanserin to treat hypoactive sexual desire disorder in premenopausal women has once again fueled the ongoing debate about medicalization of female sexual problems and the necessity of such a drug. AIM: To investigate women's attitudes toward sexuality-boosting medication (SBM) and the role of factors potentially associated with these attitudes, including sexual functioning, sexual quality of life, relationship satisfaction, and personality, in an exploratory survey. METHODS: A population sample of 159 women 18 to 73 years old (mean = 31.8) participated in this cross-sectional online survey. Study variables were assessed using a combination of validated questionnaires and self-constructed questions. MAIN OUTCOME MEASURES: Descriptive statistics in the form of proportions and percentages and correlation and moderation analyses. RESULTS: Sixty-one percent of women were willing to take SBM, mostly to increase orgasm frequency and intensity and sexual desire. Likeliness to take SBM correlated negatively with age (r = -0.24; P < .005) and with levels of arousal, lubrication, orgasm, and sexual satisfaction (P < .05 for all comparisons). Higher relationship satisfaction and conscientiousness moderated the association between willingness to take SBM and desire levels (P < .05 for the two comparisons). For desired properties of SBM, 48.2% of women considered an onset of action of "up to 1 hour" ideal, 41% preferred "less than 15 minutes," and 66.9% considered a window of action of "an hour" to be ideal. CONCLUSION: The demand for a drug to enhance sexual performance in women exists and ideally should target desire and orgasm intensity and frequency. By taking such as drug, women hope to benefit in increased sexual satisfaction and fun with sex. Furthermore, the willingness to take SBM seems to greatly depend on the woman's relationship satisfaction and some personality characteristics. Gutsche M, Burri A. What Women Want-An Explorative Study on Women's Attitudes Toward Sexuality Boosting Medication in a Sample of Swiss Women. J Sex Med 2017;14:404-412.
[Mh] Termos MeSH primário: Atitude Frente à Saúde
Satisfação Pessoal
Qualidade de Vida/psicologia
Disfunções Sexuais Psicogênicas/psicologia
[Mh] Termos MeSH secundário: Adulto
Estudos Transversais
Feminino
Seres Humanos
Meia-Idade
Psicofarmacologia
Disfunções Sexuais Psicogênicas/tratamento farmacológico
Suécia
Testosterona
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
3XMK78S47O (Testosterone)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170510
[Lr] Data última revisão:
170510
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170129
[St] Status:MEDLINE


  6 / 3236 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28089616
[Au] Autor:Pascoe JM
[Ti] Título:Foreword: Pediatric Psychopharmacology for Primary Care Clinicians.
[So] Source:Curr Probl Pediatr Adolesc Health Care;47(1):1-2, 2017 01.
[Is] ISSN:1538-3199
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Atenção Primária à Saúde
Psicofarmacologia
[Mh] Termos MeSH secundário: Criança
Seres Humanos
Transtornos Mentais
[Pt] Tipo de publicação:EDITORIAL; COMMENT
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170830
[Lr] Data última revisão:
170830
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170117
[St] Status:MEDLINE


  7 / 3236 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28089615
[Au] Autor:Smith A
[Ad] Endereço:Department of Psychiatry, Dayton Children's Hospital, Wright State University Boonshoft School of Medicine, Dayton, OH. Electronic address: SmithA2@childrensdayton.org.
[Ti] Título:Commentary: Pediatric Psychopharmacology for the Primary Care Clinician.
[So] Source:Curr Probl Pediatr Adolesc Health Care;47(1):25-26, 2017 01.
[Is] ISSN:1538-3199
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Atenção Primária à Saúde
Psicofarmacologia
[Mh] Termos MeSH secundário: Criança
Seres Humanos
Transtornos Mentais
[Pt] Tipo de publicação:JOURNAL ARTICLE; COMMENT
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170830
[Lr] Data última revisão:
170830
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170117
[St] Status:MEDLINE


  8 / 3236 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28031269
[Au] Autor:Suhara T; Chaki S; Kimura H; Furusawa M; Matsumoto M; Ogura H; Negishi T; Saijo T; Higuchi M; Omura T; Watanabe R; Miyoshi S; Nakatani N; Yamamoto N; Liou SY; Takado Y; Maeda J; Okamoto Y; Okubo Y; Yamada M; Ito H; Walton NM; Yamawaki S
[Ad] Endereço:National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Suhara, Higuchi, Takado, Maeda, and Yamada); Taisho Pharmaceutical Co., Ltd., Saitama, Japan (Drs Chaki and Omura); Takeda Pharmaceutical Co., Ltd., Kanagawa, Japan (Drs Kimura and Furusawa); Astellas Pharma I
[Ti] Título:Strategies for Utilizing Neuroimaging Biomarkers in CNS Drug Discovery and Development: CINP/JSNP Working Group Report.
[So] Source:Int J Neuropsychopharmacol;20(4):285-294, 2017 Apr 01.
[Is] ISSN:1469-5111
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Despite large unmet medical needs in the field for several decades, CNS drug discovery and development has been largely unsuccessful. Biomarkers, particularly those utilizing neuroimaging, have played important roles in aiding CNS drug development, including dosing determination of investigational new drugs (INDs). A recent working group was organized jointly by CINP and Japanese Society of Neuropsychopharmacology (JSNP) to discuss the utility of biomarkers as tools to overcome issues of CNS drug development.The consensus statement from the working group aimed at creating more nuanced criteria for employing biomarkers as tools to overcome issues surrounding CNS drug development. To accomplish this, a reverse engineering approach was adopted, in which criteria for the utilization of biomarkers were created in response to current challenges in the processes of drug discovery and development for CNS disorders. Based on this analysis, we propose a new paradigm containing 5 distinct tiers to further clarify the use of biomarkers and establish new strategies for decision-making in the context of CNS drug development. Specifically, we discuss more rational ways to incorporate biomarker data to determine optimal dosing for INDs with novel mechanisms and targets, and propose additional categorization criteria to further the use of biomarkers in patient stratification and clinical efficacy prediction. Finally, we propose validation and development of new neuroimaging biomarkers through public-private partnerships to further facilitate drug discovery and development for CNS disorders.
[Mh] Termos MeSH primário: Biomarcadores
Fármacos do Sistema Nervoso Central
Descoberta de Drogas/métodos
Neuroimagem
Neurofarmacologia/métodos
Psicofarmacologia/métodos
[Mh] Termos MeSH secundário: Descoberta de Drogas/normas
Seres Humanos
Neurofarmacologia/normas
Psicofarmacologia/normas
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW; TECHNICAL REPORT
[Nm] Nome de substância:
0 (Biomarkers); 0 (Central Nervous System Agents)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170926
[Lr] Data última revisão:
170926
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161230
[St] Status:MEDLINE
[do] DOI:10.1093/ijnp/pyw111


  9 / 3236 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27866506
[Au] Autor:do Prado-Lima PAS
[Ad] Endereço:BraIns (Brain Institute, PUCRS) InsCer (Instituto do Cérebro, PUCRS),Porto Alegre,Rio Grande do Sul,Brazil.
[Ti] Título:The surprising blindness in modern psychiatry: do guidelines really guide?
[So] Source:CNS Spectr;22(4):312-314, 2017 Aug.
[Is] ISSN:1092-8529
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Medicina Baseada em Evidências
Transtornos Mentais/tratamento farmacológico
Guias de Prática Clínica como Assunto
Psiquiatria
Psicotrópicos/uso terapêutico
[Mh] Termos MeSH secundário: Pesquisa Biomédica
Seres Humanos
Psicofarmacologia
[Pt] Tipo de publicação:EDITORIAL
[Nm] Nome de substância:
0 (Psychotropic Drugs)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171017
[Lr] Data última revisão:
171017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161122
[St] Status:MEDLINE
[do] DOI:10.1017/S1092852916000705


  10 / 3236 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26976401
[Au] Autor:Wilkening GL; Gannon JM; Ross C; Brennan JL; Fabian TJ; Marcsisin MJ; Benedict NJ
[Ad] Endereço:University of the Incarnate Word, San Antonio, TX, USA. wilkenin@uiwtx.edu.
[Ti] Título:Evaluation of Branched-Narrative Virtual Patients for Interprofessional Education of Psychiatry Residents.
[So] Source:Acad Psychiatry;41(1):71-75, 2017 Feb.
[Is] ISSN:1545-7230
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: This pilot study evaluated the utility of branched-narrative virtual patients in an interprofessional education series for psychiatry residents. METHODS: Third-year psychiatry residents attended four interprofessional education advanced psychopharmacology sessions that involved completion of a branched-narrative virtual patient and a debriefing session with a psychiatric pharmacist. Pre- and post-assessments analyzed resident learning and were administered around each virtual patient. Simulation 4 served as a comprehensive review. The primary outcome was differences in pre- and post-assessment scores. Secondary outcomes included resident satisfaction with the virtual patient format and psychiatric pharmacist involvement. RESULTS: Post-test scores for simulations 1, 2, and 3 demonstrated significant improvement (p < 0.05) from pre-test scores. Scores for simulation 4 did not retain significance. Resident satisfaction with the branched-narrative virtual patient format and psychiatric pharmacist involvement was high throughout the series (100 %; n = 18). CONCLUSIONS: Although there are important methodological limitations to this study including a small sample size and absence of a comparator group, this pilot study supports the use of branched-narrative virtual patients in an interprofessional education series for advanced learners.
[Mh] Termos MeSH primário: Simulação por Computador
Internato e Residência
Relações Interprofissionais
Narração
Psiquiatria/educação
[Mh] Termos MeSH secundário: Competência Clínica/normas
Avaliação Educacional/métodos
Seres Humanos
Farmacêuticos
Projetos Piloto
Estudos Prospectivos
Psicofarmacologia/educação
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170215
[Lr] Data última revisão:
170215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160316
[St] Status:MEDLINE
[do] DOI:10.1007/s40596-016-0531-1



página 1 de 324 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde